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Rationale. Radium-223-Dichloride (Ra-223) is an alpha-emitter, used to treat bonemetastases. Patients with highmetastatic burden
and/or with increased trabecular bone uptake could present a higher incidence of hematologic toxicity. We hypothesized that these
two factors are predictors of bone marrow failure.Material and Methods. A computer algorithm discriminated between trabecular
bone (𝐵Vol) and tumor metastases (𝑀Vol) within pretherapeutic whole-body skeletal SPECT/CT (𝑁 = 47). The program calculated
the metastatic invasion percent (INV%) as the 𝑀Vol/(𝑀Vol + 𝐵Vol) ratio and extracted the 𝐵Vol mean counts. 𝐵Vol counts were
correlated to % drop of hemoglobin (Hb), leukocytes (WBC), and platelets (PLT) after 3/6 Ra-223 cycles. Patient-specific and
computational-derived parameters were tested as predictors of hematologic toxicity withMANOVA. Results. 𝐵Vol counts correlated
with drop of Hb (𝑅 = 0,65, 𝑝 < 0.01) and PLT (𝑅 = 0,45, 𝑝 < 0.01). Appendicular 𝐵Vol counts showed a better correlation (𝑝 < 0.05,
𝑝 < 0.01, and 𝑝 < 0.001 for Hb, WBC, and PLT, resp.). INV% directly correlated with 𝐵Vol counts (𝑅 = 0.68, 𝑝 < 0.001). At
MANOVA, grade III/IV toxicity was predicted by INV% (𝑝 < 0.01), by long-bone invasion (𝑝 < 0.005), and by 𝐵Vol counts
(𝑝 < 0.05). Conclusions. In patients with significant bone tumor burden, degree of bone invasion and trabecular bone uptake are
predictors of subsequent bone marrow failure.
1. Introduction
Patients affected by castration-resistant prostate cancer
(CRPC) presentan extremelyhighincidenceofskeletalmetas-
tases [1]. In recent years, numerous novel treatment modal-
ities have been developed to treat metastasized CRPC [2–
5]. Among these, radionuclide therapy with alpha-emitting
Ra-223-Dichloride (Ra-223) has been recently approved [6].
This isotope allows obtaining a significant survival improve-
ment, alongside with satisfying pain palliation and reduction
of skeletal-related events [7–11]. Moreover, Ra-223 therapy,
owing to its short emission radius [12], is characterized
by a relatively low incidence of hematologic toxicity, when
compared with 𝛽-emitting radioisotopes [13, 14]. In fact, Ra-
223-related bone marrow failure presents an incidence of 3-
4% for grade III and 1% for grade IV reactions [10].
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However, these data are derived from a heterogeneous
CRPC population, whose patients presented very diverse
tumor burden, ranging from 2 to >20 metastases. Actually,
more than half of the enrolled population had less than
20 skeletal localizations [10]. Recent studies have however
suggested that the incidence of bone marrow failure could
be more common in patients presenting a higher number of
skeletal metastases [6, 15, 16].
Two main factors could influence the onset of bone
marrow toxicity during theRa-223 therapy: the tumor burden
per se and the metabolic intensity of nontarget trabecular
bone.
In fact, under normal conditions, active bone marrow
takes up about one-third of the available volume within the
intrabone space; this “red” bone marrow is located within
the vertebrae, the sternum, and the flat bones [17]. If this
space is invaded by metastases, hematopoietic stem cells can
home and seed in more distal hematopoietic niches in the
appendicular skeleton. As the disease inevitably progresses,
bone metastases are increasingly observed in the appendicu-
lar skeleton aswell. In this scenario, the space for healthy bone
marrow becomes also restricted and necessary compensatory
bone marrow expansion (e.g., because of Ra-223 induced
damage) is hampered.
On the other hand, radiotracer uptake within the tra-
becular skeleton, where the hematopoietic bone marrow is
located, can present significant interpatient variations [18, 19].
As Ra-223 uptake tends to mirror the one of the common
bone-seeking tracers [8, 20], a higher metabolism in the
pretherapeutic bone scintigraphy could entail a greater Ra-
223 uptake as well as a longer residence time within the
trabecular bone, possibly resulting in an overall higher dose
to the bone marrow.
The first point, that is, correlation between tumor burden
and bone marrow failure, was tested by studies employing an
automated thresholding in bone scans [21] or in PET [22].
Though interesting, the PET-threshold approach is scanner-
specific, requiring center-specific validation as well as peri-
odic recalibrations, and is therefore not readily exportable;
the planar analysis is on the other hand subject to summation
artifacts [23].
With regard to the second point, the correlation between
bone tracer uptake intensity and hematologic toxicity
remains to this day substantially unexplored.
In this paper, we applied a novel computational tool to
hybrid SPECT/CT imaging, to measure the overall tumor
volume and the radioactivity concentration in the bone mar-
row. This method uses a segmentation algorithm to identify
the trabecular bone and the metastases in the CT images,
thus avoiding the problems related to PET/scintigraphy
thresholding. Then it can extract additional data from the
coregistered metabolic images, in order to estimate the tracer
concentration in these two volumes. The goal of the present
investigation is to test the hypothesis that an enhanced intra-
bone mineral metabolism and an increased tumor burden
can predict a higher risk for bone marrow toxicity. Moreover,
the specific role of the bone marrow located within the
appendicular skeleton, which might be key in patients with
extensive axial bones metastasization, is also explored.
2. Materials and Methods
2.1. Patients’ Population and Procedures. Forty-seven adult
patients (mean age 69.5 ± 7, age range 55.5–80.8), consec-
utively admitted to our unit for pretherapeutic evaluation
of skeletal metastases from CRPC were retrospectively ana-
lyzed. Inclusion criteria comprised histologically confirmed
prostate neoplasia, evidence of prostate specific antigen
(PSA) increase in course of maximal androgen blockade,
and presence of clinically symptomatic and radiological con-
firmed skeletal metastases. Exclusion criteria were confirmed
or suspected visceral metastases, presence of grade 2 hema-
tologic toxicity at baseline, according to CTCAE criteria,
version 4.0 [24], end-stage renal disease, imminent danger
of pathologic fracture or unwillingness/incapacity to sign an
informed consent. Any previous therapy or combination of
treatments was admitted. Similarly, any entity of metastatic
burdenwas conceded andno selection on the basis of number
of metabolically active areas was performed.
Each patient underwent a baseline Tc-99m-dicarboxy-
propane-diphosphonate (DPD) whole-body bone SPECT/
CT scan, followed by six Ra-223-Dichloride injections
(Xofigo, Bayer PharmaAG, Berlin, Germany, 50KBq per Kg
of body weight), each spaced one month apart. Hemoglobin,
leukocytes (WBC), and platelets (PLT) were monitored on
a weekly basis. Percent variation of these parameters was
calculated after three and six Ra-223-Dichloride cycles.
All patients gave written informed consent for the retro-
spective analysis of the pseudonymized clinical SPECT/CT
data. The investigations were conducted in accordance with
the Helsinki Declaration and with national regulations,
after approval by the ethics committee of the University of
Tu¨bingen.
2.2. Scan Protocol. Patients were scanned on a hybrid
SPECT/CT device (Discovery 670 Pro, GE Healthcare,
Chicago, US), three hours after injection of 8–10MBq/Kg
of Tc-99M-DPD (CIS Bio, Berlin, Germany). To minimize
artifacts caused by the presence of radioactive urine in the
excretory system, patients were asked to drink at least 1000ml
of water during the uptake time and to void immediately
before the scan.
The acquisition comprised a whole-body planar scan,
followed by a whole-body SPECT/CT, from vertex up to
the distal femoral epiphyses, obtained by reconstructing
and fusing three sequential fields of view (Xeleris 3, GE
Healthcare, Chicago, USA). SPECT acquisition was carried
out with the two camera heads in H-Mode; parameters for
each field of viewwere as follows: energywindow 140.5±10%,
angular step 6∘, time per step 15󸀠󸀠. The transaxial field of view
and pixel size of the reconstructed SPECT images were 54 cm
and 5 × 5mm, respectively, with a matrix size of 128 × 128.
SPECT raw data were reconstructed using OSEM iterative
protocol (2 iterations, 10 subsets).
The 16-detector row, helical CT scanner used a gantry
rotation speed of 0.8 s and a table speed of 20mm per
rotation, with a 120 kV voltage and 10–80mA current. A
dosemodulation system (OptiDose, GEHealthcare, Chicago,
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Figure 1: Segmentation analysis of SPECT/CT images.The program detects the compact bone border, on a slice-by-slice basis, by identifying
the abrupt change of Hounsfield value (segmented edge).Themean density value of this volume is used to tell apart the trabecular bone (𝐵Vol)
from the metastases volume (𝑀Vol) on the voxels lying inside the detected surface. The program then generates two masks, corresponding to
𝐵Vol and to 𝑇Vol, which are exported to the coregistered SPECT images, from which the functional information is extracted.
US) was applied to minimize total exposure according to the
patient’s size. No contrast medium was injected.
2.3. Image Analysis. Segmentation of bone volumes on the
CT images was based on the previously validated method
[17, 25]. The computational software analysis tool was pro-
gressively developed and adapted by the joint effort of the
Department of Mathematics and the Department of Health
Sciences of the University of Genoa [17, 25–27]; it was
later improved thanks to the collaboration with the Nuclear
MedicineUnit of theUniversity of Tu¨bingen.The algorithm is
based on the principle of segmentation analysis with adaptive
threshold: it segments the osseous tissue not by aprioristically
defining aHounsfield value for bone, but by rather identifying
the bone border, on each separate slice, by recognizing the
sharp variation of attenuation value between soft and bone
tissue.
Briefly, the algorithm identifies the skeleton onCT images
by recognizing the sharp attenuation contrast between soft
tissues and outer cortical bone. In normal subjects, two
main components are identified: the outer compact bone and
the intraosseous cancellous tissue, which can be recognized
by the program in virtue of the attenuation shift between
cortical and trabecular bone (Figure 1). In patients with bone
metastases, a third volume can be identified, corresponding
to the bone metastases. This volume can also be segmented,
using the sharp contrast with the normal trabecular bone.
The bone recognition algorithm functions in two steps:
in the first step the program identifies the outer margins of
compact bone; from this point, it samples a two-pixel ring
of skeletal tissue. Thereafter, all skeletal voxels lying inter-
nally to the compact bone volume and having attenuation
coefficient equal or above the average compact bone density
are considered as tumor metastases, while the remaining
ones are labeled as normal trabecular bone (Figure 1). At
the end of the first step, the program separates the three
bone subcomponents, the compact bone, the trabecular bone
(𝐵Vol), and the bone metastases (𝑀Vol), and calculates their
volumes.Then, it proceeds to calculate the entity ofmetastatic
invasion (INV%), as the𝑀Vol/(𝑀Vol + 𝐵Vol) ratio.
In the second step, the algorithm creates two masks,
corresponding to 𝐵Vol and to𝑀Vol and exports them to the
coregistered SPECT images. Then, it measures the radioac-
tivity concentration, expressed as mean counts, within these
two volumes.
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The whole analysis is conducted first on the whole-body
skeleton. Then, separate analyses are run on the bones of the
axial skeleton (vertebrae and sternum) and for the long bones
in the appendicular skeleton (humeral and femoral shafts).
The costae are not analyzed, so as to prevent artifacts derived
from the respiratory motion.
In order to detect patients presentingmassive appendicu-
lar invasion (AI), as a sign of advanced disease, patients were
stratified in two groups on the basis of the median value of
appendicular INV%: those in the upper half were considered
to be AI-positive patients.
2.4. Statistical Analysis. The t-test for unpaired data was used
to compare values between patients’ subgroups. Correlation
between indexes was assessed with bivariate analysis, using
Pearson’s 𝑅 index.
Differences in the events’ occurrence between groups
were tested using 𝑋2 or Fisher’s exact test, as appropriate.
Multivariate analysis of variance (MANOVA) was used to
test the influence of 𝐵Vol and 𝑀Vol counts, INV%, body
weight (as it reflects the administered activity), age, PSA
values, “superscan,” and AI on the occurrence of grade III/IV
hematologic toxicity. A 𝑝 value of <0.05 was considered
significant.The SPSS statistical program (SPSS, v. 21.0, IBM,
Armonk NY, USA) was employed.
3. Results
3.1. Patients’ Characteristics. 32 out of 47 patients presented
high-risk disease [28] at diagnosis (68%). Mean disease
duration was 7.5 ± 5.8 years. On average, patients had known
skeletal metastases since 36 ± 26 months; twelve patients
(26%) had a history of skeletal-related events. Mean time
since hormone resistance onset was 30±23months andmean
PSA at the time of the bone scan was 788±1843 ng/ml. None
of the patients was therapy-na¨ıve at the time of therapy; 34
(72%) had a history of previous docetaxel therapy and 15 of
them (32%) had a history of skeletal radiation therapy. All
patients were on antihormone therapy at the time of Ra-
223-therapy. All patients exhibited extensive metastasization:
mean number of localizations, as observable on SPECT-
MIP, was 76 ± 32 (range 34–135). Patients’ characteristics are
detailed in Table 1.
3.2. Degree of Trabecular Bone Invasion and Uptake Distri-
bution. Average INV% was 28 ± 20% (range 4–71%). This
figure did not exhibit significant variation between the axial
(36±28%, range 4–78%) and the appendicular sites (31±21%,
range 1–69%).
Mean counts were higher in𝑀Vol than in 𝐵Vol and tended
to be markedly higher in the axial than in the appendicular
skeleton (Figure 2). 28 patients (59%) had a “superscan”
appearance (completely of nearly absent visualization of renal
parenchyma in the planar bone scan).
A direct correlation was noted between INV% and 𝐵Vol
counts (𝑅 = 0.68, 𝑝 < 0.001); this correlation was also
observable when considering the axial and the appendicular
skeleton separately (𝑅 = 0.65 and 𝑝 < 0.001; 𝑅 = 0.59 and
𝑝 < 0.01, resp.) as shown in Figure 3.
Table 1: Patients’ characteristics.
Feature Mean Range
Age (years) 69,5 ± 7 55–81
Weight (Kg) 72,8 ± 27,6 44–111
PSA (ng/ml) 788 ± 1843 3–9375
Gleason score 8 ± 1 5–9
Disease duration (months) 90,5 ± 69 13,7–275,8
Skeletal metastases duration
(months) 36,3 ± 26 1,1–139,8
CRPC duration (months) 30 ± 23 1,9–105
Previous docetaxel 34 (72%) -
Previous skeletal RT 12 (26%) -
Focal lesions at SPECT MIP 76 ± 32 34–135
Mean baseline hemoglobin 12 ± 2 8,8–16,2
Mean baseline leucocytes 5876 ± 1743 3100–10940
Mean baseline platelets 220 ± 66 71–351
3.3. Therapy Adherence and High-Grade Bone Marrow Tox-
icity. All patients underwent at least one Ra-223-injection,
45 (96%) underwent the first three cycles, and 32 (75%)
completed the entire six cycles of therapy. Reasons for Ra-
223 discontinuation included skeletal progression at interim
analysis by means of bone scan and CT (𝑛 = 5), spread
to visceral organs (𝑛 = 4), occurrence of grade III or
higher hematologic toxicity not amenable to control (𝑛 =
4), serious infection requiring hospitalization (𝑛 = 1), or
withdrawal of consent after therapy initiation (𝑛 = 1). For
these reasons, hematologic data after three cycles are available
for all patients, while blood counts after the complete six-
cycle therapy are present for 32 patients (75%) only.
After three cycles, four patients had grade III Hb toxicity;
two of them discontinued the treatment while the other two
continued under supportive therapy: after six cycles, one of
them recovered while the other still met the grade III Hb
toxicity criteria. Three further patients had developed grade
III Hb toxicity after six cycles.
Grade III leukopenia/neutropenia was observed after
three cycles in one patient, who subsequently recovered. One
more patient developed a grade IV leukopenia/neutropenia
after three Ra-223 injections.
In total, nine patients (19%) showed an at least grade III
bone marrow dysfunction at some point in the course of Ra-
223 treatment.
Nodifferences in the occurrence of toxicity or in the entity
of blood parameter drop were observed when categorizing
the patients on the basis of previous docetaxel/radiotherapy.
3.4.Therapy-Associated Changes in Blood Counts. After three
Ra-223 cycles, at least one parameter among Hb, WBC, and
PLT had dropped by 10–50% in 39 patients (87%); a drop
of at least 50% in any parameter was instead observed in 14
patients (30%). Correlation between whole-body 𝐵Vol counts
and drop of the above-cited parameter was direct (Hb: 𝑅 =
0.33 and 𝑝 < 0.05; WBC: 𝑅 = 0.42 and 𝑝 < 0.01 and
PLT: 𝑅 = 0.49 and 𝑝 < 0.001). At site-based analysis,
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Figure 2: Mean counts in 𝐵Vol/𝑀Vol in whole-body, axial, and appendicular skeleton.
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Figure 3: Correlation between percent metastatic invasion and mean uptake of unaffected trabecular bone.The entity of metastatic invasion
positively and tightly correlates with bone uptake within trabecular bone. Said uptake can present significant variations among patients.
percent drop correlated with appendicular 𝐵Vol mean counts
(Hb: 𝑝 < 0.05; WBC: 𝑝 < 0.001 and PLT: 𝑝 < 0.01,
Figure 4). Conversely, correlationwith axial𝐵Volmean counts
was looser and limited to WBC (𝑝 < 0.05).
At the end of the six cycles, 26/32 patients (81%) presented
at least one parameter inferior by 10–50% with respect
to baseline; 11/32 (34%) showed a ≥50% drop. Correlation
between whole-body 𝐵Vol mean counts was particularly
evident when considering variation of Hb and PLT (𝑅 =
0.65 and 𝑝 = 0.001 for Hb; 𝑅 = 0.45 and 𝑝 < 0.05
for PLT). Similar to the interim evaluation, axial 𝐵Vol mean
counts did not significantly correlate with blood element
variation; conversely, appendicular mean counts showed a
robust association with the end-of-therapy Hb, WBC, and
PLT (𝑝 < 0.05, <0.01, and <0.001, resp., Figure 4). See Table 2
for the complete layout.
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Figure 4: Correlation between appendicular 𝐵Vol mean counts and blood values drop, after three (a, c) and six (b, d) cycles of Ra-223-
Dichloride. PLT = platelets; WBC = leukocytes.
Table 2: Correlation between trabecular mean counts and parameters drop.
𝐵Vol counts AXIAL 𝐵Vol counts Appendicular 𝐵Vol counts
Hemoglobin (after 3rd cycle) −0,332∗ 0,023 −0,356∗
Leucocytes (after 3rd cycle) −0,423∗∗ −0,318∗ −0,497∗∗∗
Platelets (after 3rd cycle) −0,479∗∗∗ −0,295 −0,473∗∗
Hemoglobin (after 6th cycle) −0,644∗∗ −0,264 −0,412∗
Leucocytes (after 6th cycle) −0,308 −0,108 −0,539∗∗
Platelets (after 6th cycle) −0,451∗ −0,254 −0,628∗∗∗
∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001; MCs: mean counts.
With the exception of a sporadic association between
appendicular mean counts and interimWBC (𝑝 < 0.05), val-
ues of𝑀Vol counts in any body region were not significantly
correlated with hematologic variations (data not shown).
3.5. Role of Appendicular Invasion (AI). A significant AI was
present in 23 (49%) patients, as defined by the presence of
an appendicular INV% higher than the median value (i.e.,
>27%). Patients with AI had a more pronounced drop of
all three parameters considered (Hb, 𝑝 < 0.05; WBC, 𝑝 <
0.001; and PLT, 𝑝 < 0.01) with respect to the remaining
ones. Moreover, all the above-mentioned blood parameters
were lower after three cycles in the AI group; this difference
persisted after six cycles as well (𝑝 < 0.05, Figure 5). Six
patients (12,7%) needed at least one erythrocytes transfusion
in the course of Ra-223 therapy; all of them belonged
to the AI subgroup; moreover, all patients with grade III
bone marrow toxicity and the one patient with grade IV
leukopenia/neutropenia belonged to this subpopulation as
well (see Figure 4 for details).
3.6. MANOVA. INV% ratio predicted onset of grade III/IV
hematologic toxicity at the whole-body (𝑝 < 0.05) and in
the appendicular skeleton analysis (𝑝 < 0.01). Moreover,
presence of AI predicted the onset of bone marrow toxicity
(𝑝 < 0.005).
Similarly, mean 𝐵Vol counts predicted grade III/IV hema-
tologic toxicity in the whole-body as well as in the appendic-
ular segments (𝑝 < 0.05) (see Table 3 for details).
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Figure 5: Course of blood values over time in patients with or without significant appendicular skeleton invasion. PLT = platelets; WBC =
leukocytes. ∗𝑝 < 0.05.
Table 3: Results of multivariate analysis for grade III/IV hematologic toxicity.
Dependent variable Degrees of freedom 𝐹 value 𝑝 value
Age 1 2,555 NS
Weight 1 1,978 NS
PSA level 1 3,637 NS
Superscan 1 0,33 NS
𝐵Vol counts 1 9,346 0,016
Axial 𝐵Vol counts 1 0,134 NS
Appendicular 𝐵Vol counts 1 5,318 0,045
𝑀Vol mean counts 1 1,374 NS
Axial𝑀Vol mean counts 1 0,708 NS
Appendicular𝑀Vol mean counts 1 2,933 NS
INV% 1 9,881 0,014
INV% (axial skeleton) 1 1,509 NS
INV% (appendicular skeleton) 1 12,366 0,008
Appendicular invasion (INV% >median) 1 16 0,004
4. Discussion
Thepresent paper introduces a computational method, based
on segmentation analysis, to estimate the skeletal tumor
burden and the dose to the hematopoietic bone marrow,
situated in the trabecular bone niches. Our results confirm
that both metastatic invasion and delivered activity to the
trabecular bone can affect the bone marrow function.
In this study, we considered a patient population that
presents a relevant metastatic invasion. On average, one-
third of the available intraosseous space was occupied by
tumor localizations. Previous studies have shown that normal
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hematopoiesis roughly requires one-third of the trabecular
intraosseous space [17]. In the scenario of a 30% metastatic
invasion, a hematopoietic volume expansion would still be
possible.
However, patients presenting a skeletal metastasization
(as calculated by the INV% score) reaching the high end of
the spectrum (i.e., 60–70%) could not be able to react to a
cytotoxic insult. Moreover, previous chemo- or radiotherapy
could have already partly impaired the bone marrow reserve.
As the mechanisms of metastasization generally affect the
axial skeleton first [29], the presence of a massive metastatic
component within the long bone could reflect a scenario of
significant skeletal invasion [30].
In order to clarify the possible mechanisms of Ra-223
toxicity, a posttherapy bone marrow dosimetry would be
necessary. However, the emission spectrum of this isotope
does not allow for quantification in the clinical setting,
as the injected activity is low and the fraction of emitted
gamma-photons is too scarce. Given the reported similarity
between Ra-223 and the 99mTc-based bone-seeking tracer,
we analyzed the pattern of the diagnostic tracer distribution
in the cancellous bone of these subjects. The analysis showed
that the trabecular bone activity could exhibit a 4-fold
variation among subjects.Moreover, subjects showing amore
intense uptake in the pretherapy bone SPECT/CT had a
greater decline of hematologic parameters. This correlation
was especially observed in the long bones, probably reflecting
the above-described mechanisms, entailing a delocalization
of active bone marrow from the axial skeleton to the long
bones [25, 31–34], occurring in patients with considerable
metastatic invasion.
As a matter of fact, the activity rate measured within
the trabecular bones was strictly dependent on the entity
of the metastatic invasion: the more the intraosseous spaces
were occupied by tumor localizations, the higher the activity
measured was in the apparently unaffected trabecular tissue.
This could reflect either a tendency to instability in a skeleton
whose static mechanisms are impaired by the osteoblastic
reactions [18, 19, 35] or, possibly, the presence of microscopic
metastatic invasion that cannot yet be demonstrated at mor-
phological imaging [36]. Independently of the pathophys-
iological considerations, these data suggest that a massive
presence of metastases can impair bone marrow function
during radionuclide therapy in two ways: by restricting the
space available for bone marrow expansion and by indirectly
increasing the dose to the unaffected trabecular bone.
The hereby-presented data introduce the concept of CT-
based tumor burden analysis. This method was developed so
as to reduce intercenters as well as interdevices variations.
Nevertheless, the concept of a correlation between tumor
burden and bone marrow failure can be applied to any
tumor volume measurement method [15] and to any form of
radioisotope therapy (such as Sm-153).
This study presents some limitations. It is a retrospective
study, enrolling a relatively lownumber of patients.Therefore,
incidence of bone marrow toxicity that was reported here
cannot be directly related to those of larger trials [10, 11].
However, previous trials considered a more diverse prostate
cancer cohort, while the current study focused on the
scenario of disseminated skeletal invasion. In this line, it
confirms and extends on a computational perspective the
results reported on planar scans in a similar cohort of patients
[15].
Also, the representation of trabecular activity and blood
parameter decline, as shown in Figure 3, is somewhat skewed;
it must be accounted that the study analyzed a cohort of
patients who had undergone different treatment scheme
with a different duration before Ra-223 and whose baseline
hematopoietic reserve could have been impaired by these
therapies. However, the multivariate analysis confirms that
trabecular tropism for bone-seeking tracers is an indepen-
dent risk factor for bonemarrow toxicity, at least in the setting
of advanced disease.
Given the relatively low spatial resolution of SPECT, it
cannot be excluded that radioactivity in osteoblastic tumor
areas can at least partially contribute to the trabecular bone
uptake, due to partial volume effect. This is unavoidable
and represents a known limitation of the computational
approach, especially when applied to SPECT/CT. However,
the measured activity within metastases was not predictive of
subsequent bonemarrow failure, while the activitywithin tra-
becular bone is predictive. According to these considerations,
the contribution of the radioactivity within the metastases
is therefore less likely to have caused significant alterations
on the counts within the trabecular bone. Moreover, as the
segmentation method is based on CT images, it can be
translated onto PET/CT data, in order to obtain a better
spatial resolution.
5. Conclusions
Computational analysis of SPECT/CT images can estimate
the degree of skeletal metastatic invasion, as well as the
radioactivity concentration in the trabecular bone, where the
bone marrow is located. The analysis of these parameters
suggests that, in patients with a high skeletal tumor burden,
the incidence of bone marrow failure in the course of
radionuclide therapy could be higher than what reported
previously. Further prospective studies are needed in order
to confirm these data. The computational analysis could be
used, in selected cases, to complement the visual evaluation
and to possibly personalize the therapeutic protocols.
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